Completed PHASE1/PHASE2 INTERVENTIONAL NCT00003103

Chemotherapy in Treating Patients With Solid Tumors

A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Bladder Cancer Breast Cancer Colorectal Cancer Esophageal Cancer Head and Neck Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adult Solid Tumor, Protocol Specific

Interventions docetaxel oblimersen sodium

Updated 5 times since 2017 Last updated: Jul 1, 2013 Started: Aug 31, 1997 Primary completion: Aug 31, 2002 Completion: Aug 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Bladder Cancer and Breast Cancer, this trial is completed. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 5 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Aug 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States